SPOTLIGHT: Arcoxia vote may have big impact on Novartis

Novartis will be closely watching today's expert panel session at the FDA on Arcoxia, Merck's hoped-for successor to Vioxx. Their vote could have a big impact on Novartis' chances of successfully developing Prexige. Report